title: [Positive effect of low-activity thromboxane A synthase gene on prognosis in coronary heart disease].
abstract: OBJECTIVE
  To analyze the influence of pharmacogenetic factors on the risk of clopidogrel resistance and cardiovascular events during 18-months follow-up.
  
  
  METHODS
  Two hundred and fifty patients taking clopidogrel were examined. Platelet function was determined by optical aggregometry. Thromboxane A synthase 1 (TBS1) gene polymorphism was investigated in all the patients. The impact of TBS1 gene polymorphism on the risk of clopidogrel resistance and cardiovascular events was analyzed during 18 months of follow-up.
  
  
  RESULTS
  The carriage of TBS1 gene polymorphism AA was shown to affect the risk of clopidogrel resistance. Cardiovascular complications significantly less frequently occurred in TBSI gene polymorphism AA carriers during 18 months.
  
  
  CONCLUSIONS
  The carriage of a slow AA allele of the'TBS1 gene is suggested to be a clinically significant protective factor in the secondary prevention of coronary heart disease
authors.affiliation: I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia.
authors.forename: F Yu
authors.initials: FY
authors.lastname: Kopylov
authors.affiliation: I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia.
authors.forename: D F
authors.initials: DF
authors.lastname: Mesitskaya
authors.affiliation: I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia.
authors.forename: Yu M
authors.initials: YM
authors.lastname: Nikitina
authors.affiliation: A.N. Sysin Research Institute of Human Ecology and Environmental Hygiene, Ministry of Health of Russia, Moscow, Russia.
authors.forename: M G
authors.initials: MG
authors.lastname: Aksenova
authors.affiliation: Research Center for Effective Physical Culture and Sports, Moscow, Russia.
authors.forename: A V
authors.initials: AV
authors.lastname: Dobrovolsky
authors.affiliation: I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia.
authors.forename: O V
authors.initials: OV
authors.lastname: Lomakin
authors.affiliation: ZAO 'LAGIS' Gene Engineering Systems Laboratory, Moscow, Russia.
authors.forename: O V
authors.initials: OV
authors.lastname: Chernyi
mesh_terms: D000077144:Clopidogrel; D003327:Coronary Disease / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics; D003627:Data Interpretation, Statistical; D004351:Drug Resistance / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011110:Polymorphism, Genetic; D011379:Prognosis; D011446:Prospective Studies; D012306:Risk; D013930:Thromboxane-A Synthase / Q000235:genetics* / Q000378:metabolism; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013930:Thromboxane-A Synthase; D013988:Ticlopidine